# Eli Lilly vs Novartis: valuation, size and margins compared

URL: https://funkfolio.com/compare/lly-vs-nvs

> Eli Lilly ($1.26T, P/E 46.5) and Novartis ($300.5B, P/E 30.6) compared: size, valuation, margins, debt, cash and price change.

---

## Eli Lilly vs Novartis

Eli Lilly (LLY), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and Novartis $300.5B: Eli Lilly is valued at 4.2 times as much. Eli Lilly trades at 46.5 times earnings and Novartis at 30.6. Over the past year Eli Lilly's share price has moved +39.0% and Novartis's +25.1%.

### Key facts

- **Eli Lilly market value:** $1.26T
- **Novartis market value:** $300.5B
- **Eli Lilly P/E:** 46.5
- **Novartis P/E:** 30.6
- **Eli Lilly revenue:** $65.2B FY to 2025-12-31
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Superinvestors holding both:** 8

Market values as of 18 Nov 2026, 04:23 UTC.

Eli Lilly vs Novartis: every measure side by side

| Measure | Eli Lilly | Novartis |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Switzerland |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $1.26T higher | $300.5B lower |
| Revenue | $65.2B higher | $54.5B lower |
| Earnings | $20.6B higher | $14B lower |
| Employees | 50,000 lower | 75,267 higher |
| Total assets | $112.5B higher | $110.9B lower |
| Valuation |  |  |
| P/E | 46.5 higher | 30.6 lower |
| P/S | 19.3 higher | 5.5 lower |
| P/B | 31.3 | — |
| Dividend yield | 0.47% | — |
| Profitability |  |  |
| Operating margin | — | 32.4% |
| Balance sheet |  |  |
| Net assets | $26.5B lower | $46.1B higher |
| Total liabilities | $85.9B higher | $64.4B lower |
| Total debt | $42.5B higher | $28.7B lower |
| Cash on hand | $7.3B lower | $11.4B higher |
| Price change |  |  |
| Today | -1.13% lower | -0.67% higher |
| 1 year | +39.0% higher | +25.1% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Eli Lilly 138.5, Novartis 121.0.

- Eli Lilly (LLY)
- Novartis (NVS)

Eli Lilly and Novartis share prices over one year, rebased to 100: Eli Lilly ends at 138.5, Novartis at 121.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | LLY | NVS |
| --- | --- | --- |
| Nov 28, 2025 | 105.3 | 99.1 |
| Dec 31, 2025 | 105.2 | 104.8 |
| Jan 30, 2026 | 101.5 | 113.0 |
| Feb 27, 2026 | 103.0 | 128.2 |
| Mar 31, 2026 | 90.0 | 116.1 |
| Apr 30, 2026 | 91.5 | 112.4 |
| May 29, 2026 | 108.2 | 114.2 |
| Jun 30, 2026 | 117.4 | 119.1 |
| Jul 31, 2026 | 112.4 | 118.7 |
| Aug 31, 2026 | 113.2 | 115.6 |
| Sep 30, 2026 | 113.3 | 108.4 |
| Oct 30, 2026 | 138.7 | 122.2 |
| Nov 17, 2026 | 138.5 | 121.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (8)

- [Primecap team](https://funkfolio.com/gurus/primecap) 6.5% / 0.6%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9% / 0.1%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 1.8% / 0.7%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) 1.6% / &lt;0.1%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 1.4% / 0.3%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5% / 0.4%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / &lt;0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / 0.1%

#### Eli Lilly only (20)

- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) 4.6%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 4.0%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 3.4%
- [Cathie Wood](https://funkfolio.com/gurus/cathie-wood) 0.7%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.7%
- [Jeffrey Altman](https://funkfolio.com/gurus/jeffrey-altman) 0.6%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.5%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.4%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.4%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.4%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.4%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.3%
- [Mario Gabelli](https://funkfolio.com/gurus/mario-gabelli) 0.3%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.3%
- [Frank Sands](https://funkfolio.com/gurus/frank-sands) 0.2%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.2%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.2%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.1%
- [Rob Citrone](https://funkfolio.com/gurus/rob-citrone) 0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1%

#### Novartis only (5)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.8%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.3%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.2%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Eli Lilly / Novartis). [Who owns LLY](https://funkfolio.com/stock/LLY/superinvestors) · [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors)

### More on Eli Lilly

- [Eli Lilly (LLY) stock page](https://funkfolio.com/stock/LLY)
- [Eli Lilly market cap](https://funkfolio.com/stock/LLY/market-cap)
- [Eli Lilly revenue](https://funkfolio.com/stock/LLY/revenue)
- [Eli Lilly P/E ratio](https://funkfolio.com/stock/LLY/pe-ratio)
- [Eli Lilly operating margin](https://funkfolio.com/stock/LLY/operating-margin)
- [Eli Lilly total debt](https://funkfolio.com/stock/LLY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Eli Lilly against its closest peers

- [Eli Lilly vs Johnson & Johnson](https://funkfolio.com/compare/jnj-vs-lly)
- [Eli Lilly vs AbbVie](https://funkfolio.com/compare/abbv-vs-lly)
- [Eli Lilly vs Merck & Co](https://funkfolio.com/compare/lly-vs-mrk)
- [Eli Lilly vs UnitedHealth Group](https://funkfolio.com/compare/lly-vs-unh)

#### Novartis against its closest peers

- [Novartis vs AstraZeneca](https://funkfolio.com/compare/azn-vs-nvs)
- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Merck & Co](https://funkfolio.com/compare/mrk-vs-nvs)
- [Novartis vs Thermo Fisher Scientific](https://funkfolio.com/compare/nvs-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Eli Lilly or Novartis?**

By market value, Eli Lilly is the larger: $1.26T against $300.5B for Novartis. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $54.5B for Novartis.

**Which has the higher P/E ratio?**

Eli Lilly: 46.5, against 30.6 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has more debt?**

Eli Lilly: $42.5B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Eli Lilly and Novartis?**

In their latest 13F filings, Primecap team, Jeremy Grantham (co-founder), Ken Fisher, Rajiv Jain, Larry Robbins, Brandon Haley, Murray Stahl and Dodge & Cox team hold both.

### Cite this page

Funkfolio, “Eli Lilly vs Novartis”, data as of 18 November 2026. https://funkfolio.com/compare/lly-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
